Denali Therapeutics Inc. (DNLI) shares ended the last trading session 10.1% higher at $30.77. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.1% gain over the past four weeks. Denali is developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative and lysosomal storage diseases. The recent upward price trajectory can be attributed to positiv ...